Abstract #3250

Exenatide decreases ectopic fat accumulation but have no impact on myocardial function and perfusion in patients with obesity and type 2 diabetes

Ines Imane Abdesselam¹, Anne Dutour², Alexis Jacquier³, Frank Kober⁴, Patricia Ancel⁵, Oliver Rider⁶, Monique Bernard⁴, and Benedicte Gaborit²

¹Aix-Marseille University, CRMBM, NORT, Marseille, France, ²Aix-Marseille University, NORT, AP-HM, ³Aix-Marseille University, CRMBM, AP-HM, ⁴Aix-Marseille University, CRMBM, ⁵Aix-Marseille University, NORT, ⁶University of Oxford, OCMR

The objective of the study is to assess the impact of Exenatide on endothelial reactivity, and change in ectopic fat and cardiac function. This study included 44 patients (mean 52 years) randomized to Exenatide or reference treatment. Magnetic resonance imaging was used to assess ectopic fat accumulation, coronary vasoreactivity and cardiac function. 16-weeks of Exenatide treatement resulted in a significant improvement in glycemic control and a significant reduction of both epicardial fat and hepatic steatosis. However, we found no effect of Exenatide on myocardial function. In addition, one-week of exenatide treatment had only a modest effect on vascular reactivity, albeit non-significant.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.